Analytical and diagnostic preliminary evaluation of the new RespiFAST RG panel for the detection of influenza virus, respiratory syncitial virus, Bordetella pertussis and Mycoplasma pneumoniae

2016 ◽  
Author(s):  
Isabel Micalessi
Keyword(s):  
Influenza Virus ◽  
Mycoplasma Pneumoniae ◽  
Bordetella Pertussis ◽  
Preliminary Evaluation

The Implication of Viruses in Idiopathic Sudden Hearing Loss: Primary Infection or Reactivation of Latent Viruses?

1981 ◽  
Vol 89 (1) ◽  
pp. 137-141 ◽  
Author(s):  
Robert W. Veltri ◽  
William R. Wilson ◽  
Philip M. Sprinkle ◽  
Susan M. Rodman ◽  
Debra A. Kavesh
Keyword(s):  
Hearing Loss ◽  
Influenza Virus ◽  
Herpes Simplex ◽  
Mycoplasma Pneumoniae ◽  
Primary Infection ◽  
Sudden Hearing Loss ◽  
Serum Samples ◽  
Paired Serum ◽  
Group B

Seventy-seven paired serum samples from patients with known idiopathic sudden hearing loss (ISHL) were surveyed using viral serologic methods. Fifteen different viruses and Mycoplasma pneumoniae were the agents tested. We determined an incidence of 65% (49/77) of documented significant seroconversions to one or more of the agents surveyed. Multiple agents were involved in 24 of the 49 positive cases we studied. Influenza virus Group B in 14 (18%) and rubeola in 12 (16%) were the most prevalent, followed by Herpes simplex type 1 in 6 (8%), mumps in 6 (8%), influenza Group A3 in 6 (8%), rubella in 5 (7%), and cytomegalovirus (CMV) in 5 (7%).

Different nasopharynx and oropharynx microbiota imbalance in children with Mycoplasma pneumoniae or influenza virus infection

2020 ◽  
Vol 144 ◽  
pp. 104189 ◽  
Author(s):  
Qian Zhou ◽  
Gan Xie ◽  
Yanhong Liu ◽  
Heping Wang ◽  
Yonghong Yang ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Infection ◽  
Mycoplasma Pneumoniae ◽  
Influenza Virus Infection

scholarly journals Viral etiology in adult influenza-like illness/acute respiratory infection and predictivity of C-reactive protein

2016 ◽  
Vol 10 (07) ◽  
pp. 741-746 ◽  
Author(s):  
Hakan Cinemre ◽  
Cengiz Karacer ◽  
Murat Yücel ◽  
Aziz Öğütlü ◽  
Fatma Behice Cinemre ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Respiratory Infection ◽  
Bordetella Pertussis ◽  
Legionella Pneumophila ◽  
Acute Respiratory Infection ◽  
Influenza A ◽  
Chlamydia Pneumoniae ◽  
Influenza Virus Infection ◽  
Antibiotic Use ◽  
Influenza Like Illness

Introduction: Influenza-like illness (ILI) and acute respiratory infection (ARI) are common presentations during winter and indiscriminate antibiotic use contributes significantly to the emerging post-antibiotic era. Methodology: Otherwise healthy 152 patients, presenting to outpatient clinics with ILI/ARI, were included. Patients had history & physical, CRP, hemogram and nasopharyngeal swabs for rhinovirus A/B, influenza A/B, adenovirus A/B/C/D/E, coronavirus 229E/NL63 and OC43, parainfluenza virus 1/2/3, respiratory syncytial virusA/B, metapneumovirus and Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila and Bordetella pertussis by PCR and for ABHS culture. Results: Median (IR) age was 26.5 (16.5). Time to presentation was shorter in men (p = 0.027). Patients with rhinovirus had lower rates (20%) of myalgia (p = 0.043). Patients with influenza virus had higher rates (97%) of elevated CRP (p = 0.016). Logistic regression revealed that patients with ILI/ARI and CRP ≥ 5 mg/L were 60 times more likely to have influenza virus infection than other viral agents (OR = 60.0, 95% CI = 2.65 to 1,358.2, p = 0.010). Rhinovirus predominated in December (54%), March (36%), and April (33%). Influenza virus predominated in January (51%). Fever was most common with adenovirus (p = 0.198). All GABHS cultures were negative. Atypical organisms and Bordetella pertussis were negative in all but one patient. Conclusions: Influenza virus is the most likely pathogen in ILI/ARI when CRP ≥ 5 mg/L. This might be explained by tissue destruction. Myalgia is rare with rhinovirus probably due to absence of viremia. Negative bacteria by PCR and culture suggest unnecessary antibiotic use in ILI/ARI.

Etiology of Pertussis Syndrome

PEDIATRICS ◽  
1981 ◽  
Vol 68 (1) ◽  
pp. 148-149
Author(s):  
Ben Zion Garty ◽  
Moshe M. Drucker ◽  
Menachem Nitzan
Keyword(s):  
Chlamydia Trachomatis ◽  
Laboratory Investigation ◽  
Mycoplasma Pneumoniae ◽  
Bordetella Pertussis ◽  
Age Distribution ◽  
Previous History ◽  
Older Children ◽  
Chlamydia Trachomatis Infection ◽  
Young Infants ◽  
History Of

Keller et al1 reported the interesting finding that 91 of 100 patients with pertussis syndrome were infected with Bordetella pertussis or had been exposed to this agent. Their article, however, did not mention the precise age distribution of the patients who "ranged from six weeks to adulthood." It is possible that the etiologic factors of pertussis syndrome in young infants is somewhat different from the etiology of pertussis syndrome in older children. We believe that the laboratory investigation of pertussis syndrome during the first months of life should include examinations for Chlamydia trachomatis infection in addition to the search for Bordetella, Mycoplasma pneumoniae, and viruses, as demonstrated by the following case: A 4-week-old boy with previous history of conjunctivitis was admitted because of paroxysms of staccato cough followed by occasional vomiting or cyanosis.

scholarly journals Attenuated Bordetella pertussis Protects against Highly Pathogenic Influenza A Viruses by Dampening the Cytokine Storm

2010 ◽  
Vol 84 (14) ◽  
pp. 7105-7113 ◽  
Author(s):  
Rui Li ◽  
Annabelle Lim ◽  
Meng Chee Phoon ◽  
Teluguakula Narasaraju ◽  
Jowin K. W. Ng ◽  
...  
Keyword(s):  
Public Health ◽  
Influenza Virus ◽  
Bordetella Pertussis ◽  
Influenza A ◽  
Public Health Problem ◽  
Nasal Administration ◽  
Protective Mechanism ◽  
Global Public Health ◽  
Influenza A Viruses ◽  
Proinflammatory Mediators

ABSTRACT The threat of a pandemic spread of highly virulent influenza A viruses currently represents a top global public health problem. Mass vaccination remains the most effective way to combat influenza virus. However, current vaccination strategies face the challenge to meet the demands in a pandemic situation. In a mouse model of severe influenza virus-induced pneumonitis, we observed that prior nasal administration of an attenuated strain of Bordetella pertussis (BPZE1) provided effective and sustained protection against lethal challenge with two different influenza A virus subtypes. In contrast to most cross-protective effects reported so far, the protective window offered upon nasal treatment with BPZE1 lasted up to at least 12 weeks, suggesting a unique mechanism(s) involved in the protection. No significant differences in viral loads were observed between BPZE1-treated and control mice, indicating that the cross-protective mechanism(s) does not directly target the viral particles and/or infected cells. This was further confirmed by the absence of cross-reactive antibodies and T cells in serum transfer and in vitro restimulation experiments, respectively. Instead, compared to infected control mice, BPZE1-treated animals displayed markedly reduced lung inflammation and tissue damage, decreased neutrophil infiltration, and strong suppression of the production of major proinflammatory mediators in their bronchoalveolar fluids (BALFs). Our findings thus indicate that protection against influenza virus-induced severe pneumonitis can be achieved through attenuation of exaggerated cytokine-mediated inflammation. Furthermore, nasal treatment with live attenuated B. pertussis offers a potential alternative to conventional approaches in the fight against one of the most frightening current global public health threats.

Sign in / Sign up

Export Citation Format

Share Document